J&J Acquires Firefly Bio for $1B and Builds $1B Cell Therapy Plant

Johnson & Johnson said on June 8 that it agreed to buy Firefly Bio, a privately held biotechnology startup, for $1 billion in cash. The purchase is expected to close later this year, once regulators sign off. Separately, the company announced a US$1bn cell therapy manufacturing facility in Montgomery County, Pennsylvania, on 18 February 2025.

Firefly's crown jewel is a single piece of technology called the Firelink platform, which is designed to attack tumors driven by the KRAS protein. Firelink belongs to a class of drugs called degrader antibody conjugates, or DACs. What sets Firefly aside is that it carries a different payload. Instead of a poison, its antibody delivers a 'degrader,' which is a molecule that tags a harmful protein inside the cancer cell and marks it for destruction.

The KRAS protein drives some of the most common and deadly solid tumors, including many lung, colon, and pancreatic cancers. For decades, it shrugged off nearly every drug aimed at it, which is why doctors long called it 'undruggable.' KRAS mutations appear in roughly 20% of all cancers. Firefly's drugs are preclinical, meaning they have not yet been tested in people.

This is the second time since early 2024 that Johnson & Johnson has acquired a company developing this type of cancer drug; it paid $2 billion for Ambrx Biopharma in January 2024. The company's immune-disease drug, Stelara, faces steep competition from cheaper copies, resulting in slow sales. Its multiple myeloma medicines brought in about $4 billion in the first quarter of 2026, but one of them, Darzalex, could soon lose patent protection.

The Lower Gwynedd site addresses critical bottlenecks in cell therapy delivery. Cell therapies require individual manufacturing for each patient, creating production constraints that traditional pharmaceutical manufacturing does not face. According to Johnson & Johnson, the plant will serve thousands of patients annually while reducing costs and accelerating delivery timelines for personalised therapies.

The facility will focus on Johnson & Johnson's pipeline of advanced medicines targeting cancer, immune-mediated diseases and neurological conditions. It builds on the company's existing Pennsylvania infrastructure, where it operates ten sites covering more than 2 million square feet of manufacturing, research, distribution and office space. The project creates more than 500 skilled biomanufacturing positions once fully operational, and more than 4,000 roles will support construction.

The Pennsylvania investment is part of Johnson & Johnson's broader commitment to spend US$55bn across the US on manufacturing, research, development and technology by 2029. Johnson & Johnson estimates its annual economic impact in Pennsylvania at approximately US$10bn. The company has not disclosed a construction timeline or expected operational start date for the facility.